Scandion Oncology (Sweden) Market Value
| SCOL Stock | SEK 0.06 0 4.62% |
| Symbol | Scandion |
Scandion Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Scandion Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Scandion Oncology.
| 07/28/2024 |
| 01/24/2025 |
If you would invest 0.00 in Scandion Oncology on July 28, 2024 and sell it all today you would earn a total of 0.00 from holding Scandion Oncology AS or generate 0.0% return on investment in Scandion Oncology over 180 days. Scandion Oncology is related to or competes with ExpreS2ion Biotech, Hansa Biopharma, Fluoguide, Saniona AB, and Oncopeptides. Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer pat... More
Scandion Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Scandion Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Scandion Oncology AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 25.0 | |||
| Value At Risk | (9.38) | |||
| Potential Upside | 6.29 |
Scandion Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scandion Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Scandion Oncology's standard deviation. In reality, there are many statistical measures that can use Scandion Oncology historical prices to predict the future Scandion Oncology's volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (1.03) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | 0.615 |
Scandion Oncology Backtested Returns
Scandion Oncology owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.21, which indicates the firm had a -0.21 % return per unit of risk over the last 3 months. Scandion Oncology AS exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Scandion Oncology's Coefficient Of Variation of (494.76), variance of 28.73, and Risk Adjusted Performance of (0.16) to confirm the risk estimate we provide. The entity has a beta of -1.78, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Scandion Oncology are expected to decrease by larger amounts. On the other hand, during market turmoil, Scandion Oncology is expected to outperform it. At this point, Scandion Oncology has a negative expected return of -1.12%. Please make sure to validate Scandion Oncology's jensen alpha, treynor ratio, and the relationship between the standard deviation and total risk alpha , to decide if Scandion Oncology performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.42 |
Average predictability
Scandion Oncology AS has average predictability. Overlapping area represents the amount of predictability between Scandion Oncology time series from 28th of July 2024 to 26th of October 2024 and 26th of October 2024 to 24th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Scandion Oncology price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Scandion Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Scandion Oncology lagged returns against current returns
Autocorrelation, which is Scandion Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Scandion Oncology's stock expected returns. We can calculate the autocorrelation of Scandion Oncology returns to help us make a trade decision. For example, suppose you find that Scandion Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Scandion Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Scandion Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Scandion Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Scandion Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Scandion Oncology Lagged Returns
When evaluating Scandion Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Scandion Oncology stock have on its future price. Scandion Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Scandion Oncology autocorrelation shows the relationship between Scandion Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Scandion Oncology AS.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.